



**Supplement to the prospectus regarding the invitation to subscribe for and admission to trading of shares in Biovitrum AB (publ)**

## TABLE OF CONTENTS

<b>3</b>	Supplement to the Prospectus regarding the invitation to subscribe for and admission to trading of shares in Biovitrum AB (publ)
<b>4-5</b>	Press release from Biovitrum AB (publ) on December 21, 2009
<b>6-7</b>	Press release from Biovitrum AB (publ) on December 15, 2009

### Important information

The distribution of this Prospectus Supplement (as defined below), the Prospectus and the subscription application may, in some jurisdictions, be unlawful and these documents may not be used for the purpose of, or as part of, an offer to any person or to request any person to offer in a jurisdiction where such an offer or request to offer is not allowed or would it be deemed unlawful to make such an offer or request to such offer.

The Securities have not been and will not be registered in any state or other jurisdiction other than Sweden, Norway, Ireland and the UK and may not be offered, sold, pledged or transferred, directly or indirectly, within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the United States Securities Act of 1933 (the "Securities Act"). The Rights Issue is not directed to shareholders domiciled in Australia, Canada, Hong Kong or Japan or in any other jurisdiction where participation would require additional prospectuses, registration or measures other than those pursuant to Swedish, Norwegian, Irish or UK law. Accordingly, the Prospectus Supplement, the Prospectus and the subscription application may not be distributed in any country in which the distribution or the Rights Issue requires such measures or would conflict with regulations in such country. Acquisition of Securities in violation of the restrictions described above may be void. Persons whose possession this Prospectus Supplement may come are required to inform themselves about and comply with such restrictions. Any failure to comply with such restrictions may result in a violation of applicable securities regulations. This Prospectus Supplement has been prepared by Biovitrum based on its own information and other sources that Biovitrum considers reliable.

The Securities have not been registered and will not be registered under the Securities Act nor under the securities law of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, delivered or transferred, directly or indirectly, within the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States. There will be no public offer of the Securities in the United States. A notification of subscription of Securities in contravention of the above may be deemed to be invalid.

The Securities have not been approved or disapproved by the United States Securities and Exchange Commission, any state securities commission in the United States or any other United States regulatory authority nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Securities or the accuracy or adequacy of this document. Any representation to the contrary is a criminal offence in the United States.

The Securities are being offered and sold outside the United States in reliance on Regulation S under the Securities Act. Any offering of the Securities to be made in the United States will be made only to a limited number of existing shareholders who are reasonably believed to be qualified institutional buyers (as defined in Rule 144A under the Securities Act) pursuant to an exemption from registration under the Securities Act in a transaction not involving any public offering and who have executed and returned an investor letter to the Company. For a description of these and certain further restrictions on offers, sales and transfers of the Securities and the distribution of this Prospectus Supplement and the Prospectus, see *Restrictions on sale and transfer of securities* – headline *United States* in the Prospectus.

Until 40 days after the commencement of the Rights Issue, any offer or sale of Securities within the United States by any dealer (whether or not participating in the Rights Issue) may violate the registration requirements of the Securities Act.

Approval and registration of the Prospectus Supplement does not constitute a guarantee from the Swedish Financial Supervisory Authority that the information in the Prospectus Supplement is accurate or complete.

The Prospectus Supplement is governed by Swedish law. Disputes arising out of the contents of the Prospectus Supplement and related legal matters must be settled exclusively by Swedish courts.

## **SUPPLEMENT TO THE PROSPECTUS REGARDING THE INVITATION TO SUBSCRIBE FOR AND ADMISSION TO TRADING OF SHARES IN BIOVITRUM AB (PUBL)**

This prospectus supplement (“Prospectus Supplement”) has been prepared as a result of Biovitrum’s December 21, 2009 announcement that AstraZeneca acquires all of Biovitrum’s rights to a discovery-stage research programme aimed at treating obesity and as a result of Biovitrum’s December 15, 2009 announcement that Biovitrum advances novel factor VIII long-acting hemophilia A therapy into clinical trials. The relevant press releases are included in the Prospectus Supplement.

The Prospectus Supplement represents a supplement to the Prospectus prepared in relation to the invitation to subscribe for and admission to trading of shares in Biovitrum. The Prospectus Supplement must be read in conjunction with the Prospectus in all respects and the definitions used in the Prospectus shall also apply to the Prospectus Supplement. The Prospectus was approved and registered by the Swedish Financial Supervisory Authority on December 8, 2009 and made public on December 9, 2009. The Prospectus Supplement was approved by the Swedish Financial Supervisory Authority on December 23, 2009 in accordance with Chapter 2 Section 34 of the Swedish Financial Instruments Trading Act (1991:980). The Prospectus Supplement was published on December 23, 2009.

The Prospectus Supplement is available at the Swedish Financial Supervisory Authority’s website ([www.fi.se](http://www.fi.se)), Biovitrum’s website ([www.biovitrum.com](http://www.biovitrum.com)), Carnegie Investment Bank AB’s website ([www.carnegie.se](http://www.carnegie.se)), ABG Sundal Collier AB’s website ([www.abgsc.com](http://www.abgsc.com)) and Handelsbanken Capital Market’s website ([www.handelsbanken.se/aktuellaerbjudanden](http://www.handelsbanken.se/aktuellaerbjudanden)).

Those investors who have applied for or in any other manner consented to purchase or subscribe for Securities covered by the Rights Issue, before the publication of the Prospectus Supplement, are entitled to withdraw their registration within five working days from the publication of the Prospectus Supplement. Such withdrawal must be submitted in writing to Carnegie Investment Bank AB. A form for withdrawal of the subscription application from directly registered shareholders is available for download at Biovitrum’s website [www.biovitrum.com](http://www.biovitrum.com) and can be ordered from Carnegie Investment Bank AB at +46 8 588 694 83. Investors who have submitted their subscription application through a trustee should contact this trustee regarding withdrawal. Subscriptions that are not withdrawn will remain binding and those subscribers who wish to remain as subscribers do not need to take any further action.

## **PRESS RELEASE FROM BIOVITRUM AB (PUBL) ON DECEMBER 21, 2009**

### **Biovitrum Sells Obesity Program to AstraZeneca**

**Stockholm, Sweden – December 21, 2009 – Biovitrum AB (publ) (STO: BVT) today announced that AstraZeneca (STO: AZN) has acquired all of Biovitrum's rights to its leptin modulator program aimed at treating obesity.**

Biovitrum will receive from AstraZeneca an upfront payment of Euro 6M and milestone payments contingent on development progress and sales, as well as single digit percentage royalties. If a product is approved, the agreement allows up to a total of Euro 186M in upfront and milestone payments to Biovitrum. The leptin modulator program is currently in the preclinical phase.

Björn Wallmark, Vice President, Cardiovascular & Gastrointestinal Research at AstraZeneca, said: "AstraZeneca is committed to working towards finding new solutions to health problems that stem from diabetes and obesity, two risk factors for cardiovascular disease. We are pleased that we have obtained this discovery program. It increases the strength of our portfolio of compounds that can potentially lead to medicines that meet the needs of patients."

Peter Edman, CSO of Biovitrum, said: "We are very happy that this exciting and completely novel approach to treat obese patients will continue to be developed through AstraZeneca, a company with a long heritage and strong presence in the cardiovascular disease area. We are sure that AstraZeneca will continue to develop the opportunity in a capable way and potentially add new treatment options for obese patients."

### **About Obesity**

Obesity is widely agreed to be one of largest and most rapidly growing health problems in adults today, amounting to a global epidemic. The World Health Organization projected that, in 2005, 1.6 billion adults (aged 15+) worldwide were overweight, of whom an estimated 400 million were obese. By 2015 it is expected that 2.3 billion adults will be overweight and more than 700 million will be obese<sup>1</sup>. In the US, almost two thirds of the population are overweight (67%), and nearly one third (34%) are clinically obese<sup>2</sup>. Even being only moderately overweight increases the risk of developing diabetes and cardiovascular disease<sup>3</sup>.

Although many options are available to help people lose weight, most have proven to be relatively ineffective in the long-term.

1. World Health Organisation. Health Topics: Obesity and Overweight fact sheet number 311, September 2006.

[www.who.int/mediacentre/factsheets/fs311/en/index.html](http://www.who.int/mediacentre/factsheets/fs311/en/index.html)

2. Health, United States 2008: with special feature on the health of young adults. Centers for Disease Control and Prevention.

[www.cdc.gov/nchs/data/08/08.pdf#070](http://www.cdc.gov/nchs/data/hus/08/08.pdf#070)

3. Burton BT, Foster WR. Health implications of obesity: an NIH Consensus Development Conference. J Am Diet Assoc 1985;85:1117-21

## **About Biovitrum**

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit [www.biovitrum.com](http://www.biovitrum.com).

## **About AstraZeneca**

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US\$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: [www.astrazeneca.com](http://www.astrazeneca.com)

## **For more information please contact:**

### **Biovitrum AB (publ)**

Erik Kinnman, EVP Investor Relations

Phone: +46 73 422 15 40

[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

Peter Edman, CSO

Phone. +46 8 697 21 77

*Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on December 21, 2009 at 5.00 p.m. CET.*

## **PRESS RELEASE FROM BIOVITRUM AB (PUBL) ON DECEMBER 15, 2009**

### **Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy into Clinical Trials**

**Stockholm, Sweden - Dec 15, 2009 - Biovitrum AB (publ) (STO: BVT) today announced that the first patient was dosed in a phase I/IIa study of its long-acting fully-recombinant Factor VIII Fc fusion (rFVIII Fc) protein. The phase I/IIa open-label study will assess the safety, tolerability and pharmacokinetics of rFVIII Fc in severe, previously-treated, hemophilia A patients. The rFVIII Fc program and international study are partnered with Biogen Idec (NASDAQ: BIIB).**

Hemophilia A patients require frequent Factor VIII injections, which create a significant burden for these individuals. The rFVIII Fc molecule is being investigated for the potential to prolong protection from bleeding and reduce the frequency of injections for both prophylaxis and on-demand therapy in Hemophilia A. Preclinical studies showed improved half-life of rFVIII Fc, which is based on Biogen Idec's monomeric Fc-fusion technology (recently presented 7 December 2009 at the American Society of Hematology conference).

“We are excited about bringing rFVIII Fc into the clinical stage together with Biogen Idec and, thereby adding another significant collaboration project to the ongoing recombinant Factor IX Fc fusion (rFIX Fc) clinical program. The innovative rFVIII Fc program holds great potential in offering true value to hemophilia A patients, and is thus a prioritized therapeutic and business area within Biovitrum,” said Peter Edman, CSO of Biovitrum.

#### **About Hemophilia A**

Hemophilia A is a rare, inherited disorder in which the ability of a person's blood to clot is impaired. Hemophilia A occurs in about 1 in 10,000 male births annually and is caused by having substantially reduced or no factor VIII protein, which is needed for normal blood clotting. People with hemophilia A therefore need injections of factor VIII to restore the coagulation process and prevent frequent bleeds that could otherwise lead to pain, irreversible joint damage and life-threatening hemorrhages. Prophylaxis treatment with infusions three times per week or every second day to maintain a sufficient circulating level of coagulation factor is being increasingly used, and long-term studies demonstrate that such regimens increase the patient's life expectancy and greatly reduce if not eliminate progressive joint deterioration. The current global market for recombinant Factor VIII products is over 4 BUSD annually.

#### **About Biovitrum**

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise

and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit [www.biovitrum.com](http://www.biovitrum.com).

**For more information please contact:**

**Biovitrum AB (publ)**

Erik Kinnman, EVP Investor Relations

Phone: +46 73 422 15 40

[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

Peter Edman, CSO

Phone: +46 8 697 21 77

*Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on December 15, 2009 at 08:30 a.m. CET.*